The C-X-C motif chemokine receptor 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12) axis drives immune exclusion in pancreatic ductal adenocarcinoma (PDA). Building on our preclinical data, we conducted the first stage of an open-label, single-arm phase 2 clinical trial combining CXCR4 inhibition (motixafortide), PD-...
A. Raufi, Edridge K. D'Souza, Michael S. May et al.· Nature Communications· 0 citations
If tumor specific immune responses to immunotherapy are greatest prior to nephrectomy, then treatment with nivolumab and cabozantinib both prior to and after cytoreductive nephrectomy (CN) would lead to maximal peripheral and intra-tumoral specific immune responses and higher rates of achieving a complete response.
K. Runcie, Calvin Park, M. Ornstein et al.· The Oncologist· 0 citations
A single-cell regulatory network analysis of therapy-associated cell state remodeling to inform combination strategies in osteosarcoma and single-cell profiling reveals drug effects missed by bulk efficacy measures is extended.
J. Pavisic, Chelsey M. Burke, Dao-Qi You et al.· Cancer Research· 0 citations
The authors apply ARACNe and metaVIPER to published scRNA-seq datasets to characterize pancreatic cancer subtypes, identifying six distinct cell states as well as their mechanistic determinants.
P. Laise, Mikko M. Turunen, Álvaro Curiel-García et al.· Nature Genetics· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
